IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA). Investors who purchased or otherwise acquired BioAmber shares between January 23, 2017 and March 16, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 17, 2017 lead plaintiff deadline.
If you purchased shares of BioAmber during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
BioAmber revealed poor financial outcomes for the 2016 fiscal year, failing to meet its prior revenue guidance by $1.3 million. On an earnings conference call, President Fabrice Orecchioni of BioAmber, attributed poor results to “pricing pressures” and “a disruption from a large customer that was expected to purchase 2.8 million of succinic acid in Q4 2016, but due to a technical problem in its manufacturing facility postponed the order to 2017.”
When this information was offered to the investing public, BioAmber stock fell, causing investors harm.
If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.